Introduction {#s1}
============

Approximately one million people are diagnosed with gastric cancer each year, making it the fourth most common cancer type and the second leading cause of cancer-related death worldwide, with an estimated 800,000 deaths caused by the disease [@pone.0049424-Kamangar1]. More new cases are diagnosed in China than in other countries around the world [@pone.0049424-Jemal1], and most of those patients are diagnosed at an advanced disease stage [@pone.0049424-Wang1], [@pone.0049424-Wei1]. Surgery is the only way to cure gastric cancer in these patients. Gastric resection may be classified by the extent of lymph node dissection at surgery. A D2 radical gastrectomy is considered a standard surgical procedure in Asian countries especially Japan, South Korea and China, although Western investigators have not found a survival advantage when extensive lymphadenectomy is compared with a D1 resection [@pone.0049424-Bonenkamp1]--[@pone.0049424-McCulloch1]. The prognosis for gastric cancer patients undergoing a D2 resection remains very poor, which may be due to the inaccurate post-surgical staging for patients and a subsequent inappropriate choice of adjuvant treatment.

In 2010, the AJCC's (American Joint Committee on Cancer) 7th edition TNM classification of malignant tumours for gastric cancer was published [@pone.0049424-SobinLH1]. Primary tumours (T), regional lymph nodes (N) and metastasis (M) are the three most important independent prognostic factors for gastric cancer patients. Among these factors, the regional lymph nodes are the most difficult to accurately stage. The number of lymph nodes to be removed in surgery is not clearly defined in a D2 resection. The resection of 15 nodes is recommended in the AJCC's TNM staging system. Another question is whether more accurate staging can be achieved by removing more lymph nodes. Schwarz et al. [@pone.0049424-Schwarz1] found that a stage-based survival prediction depends on the total lymph node number and the number of negative lymph nodes. Other investigators have suggested that 20, or even 30, lymph nodes is a better choice than 15 [@pone.0049424-Chen1], [@pone.0049424-Liang1]. Some investigators suggest the use of the metastatic lymph node ratio to eliminate the variability generated by removing different numbers of lymph nodes. Additionally, they found that the metastatic lymph node ratio is an independent prognostic factor [@pone.0049424-Lee1]--[@pone.0049424-Lee2]. The metastatic lymph node ratio has not previously been accepted as a standard for staging gastric cancer. The reasons for this lack of acceptance may be that different investigators have used a variety of dividing methods to determine the metastatic lymph node ratios, and stronger evidence is required to support the metastatic lymph node ratio as a standard for determining the N portion of the TNM staging system for gastric cancer as a replacement for the current standard of assessing the regional lymph node numbers.

In our study, we investigated whether recommended 15 lymph nodes for use in the TMN staging system is sufficient for evaluating gastric cancer and whether 30 lymph nodes would be more accurate. Additionally, we assessed whether our metastatic lymph node ratio dividing method, adapted from the AJCC's 7^th^ TNM staging system, is helpful for the patients with fewer than 15 harvested lymph nodes.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

All patients were provided written informed consent for their information to be stored in the hospital database. Study approval was obtained from the independent ethics committees at Cancer Center of Sun Yat-Sen University. The study was undertaken in accordance with the ethical standards of the World Medical Association Declaration of Helsinki.

Eligibility Criteria {#s2b}
--------------------

The eligibility requirements included the following: (1) Patients had gastric carcinoma identified by histopathological examination, (2) underwent gastrectomy, (3) presented absence of identifiable distant metastasis, such as liver, lung and distal lymph nodes, (4) presented no history of another synchronous malignancy, (5) presented no recurrent gastric cancer or remnants of gastric cancer, (6) received no neoadjuvant therapy, (7) survived in the perioperative period and (7) had complete follow-up data collection. The procedures of tumour resection and the D2 lymphadenectomy performed by experienced surgeons were similar in all patients undergoing radical resection.

Surgical Procedures {#s2c}
-------------------

According to the guidelines of the Japanese Gastric Cancer Association (JGCA), the stomach was divided anatomically into upper, middle and lower portions. The three portions were defined by subdividing both the lesser and greater curvatures into three equal lengths [@pone.0049424-JapaneseGastricCancer1]. The type of gastrectomy and extent of the D2 dissection were determined by the tumour location ([Figure 1](#pone-0049424-g001){ref-type="fig"}) [@pone.0049424-JapaneseGastricCancer1]. The aim of any oncological resection was to achieve en-bloc resection of the gastric segment and surrounding lymph nodes to obtain adequate oncological clearance. Forty-eight patients received a concurrent splenectomy as part of their surgical treatment, and 23 of these also underwent a resection of the pancreatic body and tail.

![The type of gastrectomy and the extent of the D2 dissection were determined by the tumour location.](pone.0049424.g001){#pone-0049424-g001}

### Method for recategorising N staging {#s2c1}

It is well known that in the AJCC's TNM staging system, the cut-off values to divide the patients into different N groups are 0, 2 and 6 regional lymph nodes. Thus, we evaluated the N staging of patients by the metastatic lymph node ratio with 0, 0.13 (2/15), and 0.40 (6/15) as our cut-off values. According to the metastatic lymph node ratio, we separated the patients who had fewer than 15 lymph nodes harvested into 4 groups \[0, 0--0.13 (2/15), 0.13--0.40 (6/15) and greater than 0.40\] and re-categorised these 4 groups into the N0, N1, N2, and N3a groups. These groups were then combined with other patients who had greater than 15 lymph nodes harvested to create a revised N staging.

Patient Characteristics {#s2d}
-----------------------

We included 1,101 patients who underwent gastrectomy at the Sun Yat-sen University Cancer Center between January 2001 and December 2010. The postoperative pathological results include tumour size, histological type, margin, adjacent tissues and neighbouring organs, retrieved lymph nodes, metastatic lymph nodes, and pTNM staging. The eligibility criteria include histologically confirmed R0 resection, which was defined as no residual macroscopic or microscopic tumour. Patients with distant metastases or carcinoma of the gastric stump after a gastric resection for benign disease were excluded from the study.

Patient Follow-up {#s2e}
-----------------

After treatment, patients with advanced gastric cancer were monitored every 2--3 weeks for six months postoperatively and then every 3 months for the first 2 years. Patients with early stage gastric cancer were required to have a further consultation with the doctor every 3 months for the first 2 years. All of the patients were monitored every 6 months thereafter. Telephone calls and letters were used to assess patients who could not be physically present for follow-up. Complete data were collected from all 1101 patients from the time following treatment until July 2011. The follow-up period ranged from 6 to 120 months (median, 41 months).

Statistical Analysis {#s2f}
--------------------

The Kappa and Chi-squared tests were used to compare the clinicopathological variables between the groups with different numbers of harvested lymph nodes. Univariate survival analysis was performed using the Kaplan-Meier method. Survival curves were compared with the log-rank test. Multivariate statistical survival analysis was performed using the Cox regression. Analyses were performed with the SPSS software version 20.0 for Windows (SPSS, Inc., Chicago, IL). Statistical significance was defined as P\<0.05.

Results {#s3}
=======

Patient Demographics {#s3a}
--------------------

In total, 2 patients died in the perioperative period, secondary to anastomotic leakage and renal failure. There were another 94 patients excluded from our study because of incomplete follow-up data. The total number of patients included in our study is 1101. The median age of them was 59 years old (range: 18--83). Of these patients, 752 were male and 349 were female. The 5-year survival of the whole patient group was 41.0%, with a median survival of 61.2 months. The patient clinicopathological characteristics are presented in [Table 1](#pone-0049424-t001){ref-type="table"}. The average number of lymph nodes harvested was 21.51±12.42 (mean ± standard deviation) and a median of 20 (range: 1--68). The average number of metastatic lymph nodes harvested was 4.26±6.04 (range:0--56). According to the 7^th^ AJCC's TNM staging system for gastric cancer, there were 351, 219, 224, 233 and 74 patients in the N0, N1, N2, N3a and N3b groups, respectively. There were 93, 65, 41, 773 and 129 patients in the T0, T1, T2, T3, T4a and T4b groups, respectively. The clinicopathological factors for all 1101 patients are presented in [Table 1](#pone-0049424-t001){ref-type="table"}.

10.1371/journal.pone.0049424.t001

###### Clinical pathological data for gastric cancer patients with different numbers of harvested lymph nodes.

![](pone.0049424.t001){#pone-0049424-t001-1}

  Clinical pathological data                         Fewer than 15 harvested lymph nodes (n  = 346 cases)     Harvested lymph nodes (15--29) (n  = 601 cases)   Greater than 30 harvested lymph nodes (n  = 154 cases)                                
  ------------------------------------------------ --------------------------------------------------------- ------------------------------------------------- -------------------------------------------------------- -------- ------- ----- ------ ---------
  Age (Years)                                                               Median                                                  61                                                    57                               58     0.316               
                                                                             Range                                                28--83                                                18--82                           22--76                       
  Sex                                                                        Male                                                   245                                                  70.8                             401     66.7    106   68.8  
                                                                            Female                                                  101                                                  29.2                             200     33.3    48    31.2    0.424
  Tumour location                                                       Gastric cardia                                              211                                                  61.0                             232     38.6    42    27.3  
                                                                            Middle                                                  29                                                   8.4                              115     19.1    31    20.1  
                                                                            Antrum                                                  84                                                   24.3                             234     38.9    75    48.7  
                                                                         Total stomach                                               2                                                   0.6                               7       1.2     4    2.6   
                                                       Remnant stomach[\*](#nt101){ref-type="table-fn"}                             20                                                   5.8                               13      2.2     2    1.3    \<0.001
  Surgery                                                            Proximal gastrectomy                                           218                                                  63.0                             219     36.4    42    27.3  
                                                                      Distal gastrectomy                                            93                                                   26.9                             293     48.8    85    55.2  
                                                                       Total gastrectomy                                            35                                                   10.1                              89     14.8    27    17.5   \<0.001
  Tumour size                                                               \<3 cm                                                  52                                                   15.0                             101     16.8    14    9.1   
                                                                             ≥3 cm                                                  294                                                  85.0                             500     83.2    140   90.9    0.059
  Borrmann type                                                                I                                                    12                                                   3.8                               18      3.4     2    1.3   
                                                                              II                                                    184                                                  57.5                             286     53.4    60    39.5  
                                                                              III                                                   107                                                  33.4                             210     39.2    77    50.7  
                                                                              IV                                                    17                                                   5.3                               22      4.1    13    8.6     0.002
  Histological grade                                                 High-differentiation                                            4                                                   1.2                               6       1.0     0     0    
                                                                    Median-differentiation                                          111                                                  32.1                             147     24.5    23    14.9  
                                                                      Low-differentiation                                           164                                                  47.4                             330     54.9    102   66.2  
                                                    Poor-differentiation[\*\*](#nt102){ref-type="table-fn"}                         67                                                   19.4                             118     19.6    29    18.8    0.001
  T staging[\*\*\*](#nt103){ref-type="table-fn"}                              T1                                                    26                                                   7.5                               65     10.8     2    1.3   
                                                                              T2                                                    16                                                   4.6                               45      7.5     4    2.6   
                                                                              T3                                                     9                                                   2.6                               32      5.3     0    0.0   
                                                                              T4a                                                   233                                                  67.3                             348     57.9    133   86.4  
                                                                              T4b                                                   62                                                   17.9                             111     18.5    15    9.7    \<0.001
  N staging[\*\*\*](#nt103){ref-type="table-fn"}                              N0                                                    133                                                  38.4                             185     30.8    33    21.4  
                                                                              N1                                                    79                                                   22.8                             119     19.8    21    13.6  
                                                                              N2                                                    94                                                   27.2                              87     14.5    43    27.9  
                                                                              N3a                                                   40                                                   11.6                             156     26.0    37    24.0  
                                                                              N3b                                                    0                                                   0.0                               54      9.0    20    13.0   \<0.001
  Adjuvant Chemotherapy                                                       Yes                                                   254                                                  73.4                             442     73.5    121   78.6  
                                                                              No                                                    92                                                   26.6                             159     26.5    33    21.4    0.410

These 35 remnant stomach patients all had a more than 5 years history of the gastrectomy because of the gastric ulcer.

Poorly-differentiated cells: signet ring cell carcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, etc.

The T and N stagings for this group of patients are defined according to the AJCC's 7^th^ TNM staging system for gastric cancer.

Significance of the Differing Numbers of Harvested Lymph Nodes on the Prognosis of Different N Staging {#s3b}
------------------------------------------------------------------------------------------------------

There were 346, 601 and 154 patients who had 0--14, 15--30 and more than 30 lymph nodes harvested, respectively. Their median survival times were 44.94, 46.62 and 42.82 months, respectively (p = 0.003). The results are shown in [figure 2A](#pone-0049424-g002){ref-type="fig"}.

![The survival of patients with different numbers of harvested lymph nodes.\
A The median survival times of patients who had 0--14, 15--30 and more than 30 lymph nodes harvested in the study were 44.94, 46.62 and 42.82 months, respectively (p = 0.003). B The median survival times of patients who had 0--14, 15--30 and more than 30 lymph nodes harvested in the N0 group were 45.43, 54.28 and 66.95 months, respectively (p = 0.068). C The median survival times of patients who had 0--14, 15--30 and more than 30 lymph nodes harvested in the N1 group were 49.22, 44.25 and 56.72 months, respectively (p\<0.001). D The median survival times of patients who had 0--14, 15--30 and more than 30 lymph nodes harvested in the N2 group were 43.94, 47.97 and 35.19 months, respectively (p = 0.042). E The median survival times of patients who had 0--14, 15--30 and more than 30 lymph nodes harvested in the N3a group were 32.88, 42.76 and 23.50 months, respectively (p = 0.016). F The median survival times of patients who had 15--30 and more than 30 lymph nodes harvested in the N3b group were 22.48 and 36.0 months, respectively (p = 0.199).](pone.0049424.g002){#pone-0049424-g002}

In the N0 group, there were 133, 186 and 32 patients with 0--14, 15--30 and more than 30 lymph nodes harvested, respectively. Their median survival times were 45.43, 54.28 and 66.95 months, respectively (p = 0.068). These results are shown in [figure 2B](#pone-0049424-g002){ref-type="fig"}.

In the N1 group, there were 79, 119 and 21 patients with 0--14, 15--30 and more than 30 lymph nodes harvested, respectively. Their median survival times were 49.22, 44.25 and 56.72 months, respectively (p\<0.001). These results are shown in [figure 2C](#pone-0049424-g002){ref-type="fig"}.

In the N2 group, there were 94, 87 and 43 patients with 0--14, 15--30 and more than 30 lymph nodes harvested, respectively. Their median survival times were 43.94, 47.97 and 35.19 months, respectively (p = 0.042). These results are shown in [figure 2D](#pone-0049424-g002){ref-type="fig"}.

In the N3a group, there were 40, 156 and 37 patients with 0--14, 15--30 and more than 30 lymph nodes harvested, respectively. Their median survival times were 32.88, 42.76 and 23.50 months, respectively (p = 0.016). These results are shown in [figure 2E](#pone-0049424-g002){ref-type="fig"}.

In the N3b group, there were 53 and 21 patients with 15--30 and more than 30 lymph nodes harvested, respectively. Their median survival times were 22.48 and 36.0 months, respectively (p = 0.199). The results are shown in [figure 2F](#pone-0049424-g002){ref-type="fig"}.

Significance of the Metastatic Lymph Node Ratio on the Prognosis of Patients with Different N Stagings who had Fewer than 15 Lymph Nodes Harvested {#s3c}
--------------------------------------------------------------------------------------------------------------------------------------------------

We categorised the patients in this study by their metastatic lymph node ratios: 0, 0--0.13 (2/15), 0.13--0.40 (6/15) and greater than 0.40; there were 351, 195, 270 and 285 patients in these 4 groups, respectively. Their median survival times were 75.0, 62.5, 51.4 and 31.6 months, respectively (p\<0.001). The survival curve is shown in [Figure 3A](#pone-0049424-g003){ref-type="fig"}. For the patients with fewer than 15 harvested lymph nodes, there were 133, 21, 89 and 103 patients in the 4 groups, respectively. Their median survival times of these 4 groups were 70.6, 50.5, 53.5 and 30.7 months, respectively (p\<0.001). The survival curve is shown in [Figure 3B](#pone-0049424-g003){ref-type="fig"}.

![The survival of patients with different metastatic lymph nodes ratio.\
A The median survival times of patients who had metastatic lymph node ratios of 0, 0--0.13 (2/15), 0.13--0.40 (6/15) and more than 0.40 in the study were 75.0, 62.5, 51.4 and 31.6 months, respectively (p\<0.001). B The median survival times of patients who had metastatic lymph node ratios of 0, 0--0.13 (2/15), 0.13--0.40 (6/15) and more than 0.40 in the group with fewer than 15 harvested lymph nodes group were 70.6, 50.5, 53.5 and 30.7 months, respectively (p\<0.001). C The median survival times of patients in the N1, N2 and N3a groups, those patients who had at least one metastatic lymph node in the fewer than 15 nodes that were harvested, were 46.2, 41.8 and 30.9 months, respectively (p = 0.131). D The median survival times of patients whose metastatic lymph node ratios were 0, 0--0.13 (2/15), 0.13--0.40 (6/15) and more than 0.40 in the group who had at least one metastatic lymph node in the fewer than 15 nodes that were harvested were 53.5, 53.5 and 30.7 months, respectively (p\<0.001).](pone.0049424.g003){#pone-0049424-g003}

We focused on the patients who had fewer than 15 lymph nodes harvested and were found to have at least one metastatic lymph node. There were 213 patients in this category. According to the AJCC's TNM staging system, there were 79, 94 and 40 patients in N1, N2 and N3a groups, respectively; their median survival times were 46.2, 41.8 and 30.9 months, respectively (p = 0.131). A survival curve is shown in [Figure 3C](#pone-0049424-g003){ref-type="fig"}. According to the metastatic lymph node ratio, there were 21, 89 and 103 patients in each group; their median survival times were 53.5, 53.5 and 30.7 months, respectively (p\<0.001). A survival curve is shown in [Figure 3D](#pone-0049424-g003){ref-type="fig"}.

Univariate and Multivariate Analyses for Restaging the N Staging of these Gastric Cancer Patients {#s3d}
-------------------------------------------------------------------------------------------------

According to the metastatic lymph node ratio, we separated the patients who had fewer than 15 lymph nodes harvested into 4 groups \[0, 0--0.13 (2/15), 0.13--0.40 (6/15) and more than 0.40\], and re-categorised these patients into the N0, N1, N2 and N3a groups. There were 351, 161, 219, 296 and 74 patients in the N0, N1, N2, N3a and N3b groups, respectively. Their median survival times were 74.6, 64.9, 54.5 37.7 and 31.6 months, respectively (p\<0.001). A survival curve is shown in [Figure 4](#pone-0049424-g004){ref-type="fig"}.

![The median survival times of patients in the re-categorised N1, N2, N3a and N3b groups patients were 74.6, 64.9, 54.5 37.7 and 31.6 months, respectively (p\<0.001).](pone.0049424.g004){#pone-0049424-g004}

In the univariate analysis, the tumour size, tumour position, histological grade, Borrmann type, T staging, premier N staging, and restaged N staging significantly correlated with the overall survival ([Table 2](#pone-0049424-t002){ref-type="table"}). In the multivariate analysis, the number of lymph nodes harvested, T staging and premier N staging were independent factors ([Table 3](#pone-0049424-t003){ref-type="table"}). When we included the restaged N staging in the Cox's regression model, the histological grade, T staging, premier N staging and restaged N staging were independent factors ([Table 4](#pone-0049424-t004){ref-type="table"}). The hazard ratio (HR) value of the restaged N staging system was higher than that of the premier N staging.

10.1371/journal.pone.0049424.t002

###### Univariate analysis of the overall survival in local, late-stage gastric cancer patients.

![](pone.0049424.t002){#pone-0049424-t002-2}

  Variables                                n    5-year survival rate %   Median survival (months)   P value
  -------------------------------------- ----- ------------------------ -------------------------- ---------
  **All 1101 gastric cancer patients**                                                             
  **Tumour location**                                                            \<0.001           
  Gastric cardia                          485             40                       60.1            
  Middle                                  175             27                       48.6            
  Antrum                                  393             51                       60.3            
  Total stomach                           13              32                       41.6            
  Remnant stomach                         35              0                        37.4            
  **Tumour size**                                                                                   \<0.001
  \<3 cm                                  167             64                       67.4            
  ≥3 cm                                   934             37                       58.9            
  **Borrmann type**                                                                                 \<0.001
  I                                       32              44                       53.4            
  II                                      530             38                       63.6            
  III                                     394             36                       49.8            
  IV                                      52              18                       32.4            
  **Histological grad**e                                                                             0.007
  High-differentiation                    10              90                       76.4            
  Median-differentiation                  281             50                       58.4            
  Low-differentiation                     596             36                       60.9            
  Poor-differentiation                    214             33                       52.4            
  **T staging**                                                                                     \<0.001
  T1                                      93              93                       80.1            
  T2                                      65              77                       65.9            
  T3                                      41              77                       70.3            
  T4a                                     714             35                       58.9            
  T4b                                     188             21                       39.6            
  **N staging**                                                                                     \<0.001
  N0                                      351             49                       64.5            
  N1                                      219             53                       75.7            
  N2                                      224             47                       48.5            
  N3a                                     233             29                       39.9            
  N3b                                     74              19                       31.5            
  **Lymph nodes harvested**                                                                          0.003
  0--14                                   346             33                       44.1            
  15--29                                  601             38                       64.0            
  30--                                    154             38                       50.6            
  **Restaged N staging**                                                                            \<0.001
  N0                                      351             49                       74.6            
  N1                                      161             57                       64.9            
  N2                                      219             53                       54.5            
  N3a                                     296             27                       37.7            
  N3b                                     74              19                       31.6            

Discussion {#s4}
==========

Lymph node metastasis is one of the most important prognostic factors in gastric cancer. The AJCC's 7^th^ TNM staging system for gastric cancer is commonly used in the clinic. However, this system recommends the dissection of more than 15 lymph nodes for N staging, except for the N0 patients. It is unclear whether the 15 nodes can be a standard for the D2 radical gastrectomy, or whether 30 would be better. Another argument is the loose definition of the D2 dissection [@pone.0049424-Ajani1]. A recommended number of lymph nodes to dissect intraoperatively may help standardise the surgical procedure. Patients may have fewer than 15 lymph nodes harvested for many reasons. Two main reasons are that the number of lymph nodes harvested is dependent both on surgeon technique as well as pathologist experience and that some lymph nodes were too small to be found by surgeons and pathologists. The main problems were the method for staging these patients, the type of therapy to administer and the survival prognosis.

10.1371/journal.pone.0049424.t003

###### Multivariate analyses of the overall survival in gastric cancer patients (Cox regression model, without the re-staged N system).

![](pone.0049424.t003){#pone-0049424-t003-3}

  Variable                          HR        95% CI      P value
  ------------------------------- ------- -------------- ---------
  OS in gastric cancer patients                          
  Tumour location                  0.976   0.889--1.071    0.608
  Tumour size                      1.226   0.863--1.742    0.256
  Borrmann type                    1.103   0.943--1.289    0.220
  Histological grade               1.148   0.999--1.320    0.051
  T staging                        1.501   1.285--1.753   \<0.001
  N staging                        1.363   1.257--1.479   \<0.001
  Lymph nodes harvested            0.724   0.622--0.843   \<0.001

Abbreviations: OS, overall survival; HR, hazard ratio; CI, confidence interval.

In our study, there were 346 patients with fewer than 15 lymph nodes harvested and 154 patients with more than 30 lymph nodes harvested. Some investigators have found that if the number of harvested lymph nodes is smaller, down-migration of the N stage may occur and conversely if the number is larger, up-migration of the N stage may occur [@pone.0049424-Ichikawa1]--[@pone.0049424-Aurello1]. We found that the prognosis of patients with 15--29 harvested lymph nodes was not significantly different from those with more than 30 nodes harvested in every N staging category (N0∶67.2 vs. 65.1 mo; N1∶65.0 vs. 61.5 mo; N2∶50.3 vs. 55.7 mo; N3a: 40.1 vs. 43.6 mo; N3b: 25.8 vs. 23.8 mo). We believe that the N staging would be accurate for a large number of harvested lymph nodes. Through our analysis, we found that the prognosis for patients with more than 30 lymph nodes harvested is better than those with fewer than 15 lymph nodes harvested, in every N stage. There was statistical significance for all N stages (N0∶59.7 vs. 66.6 mo, p = 0.027; N1∶60.5 vs. 63.5 mo, p\<0.001; N2∶41.8 vs. 52.8 mo, p = 0.033; N3a: 30.9 vs. 41.5 mo; p = 0.028). There were down-migrations observed for the patients who had fewer than 15 lymph nodes harvested, which supports the AJCC's recommendation that a minimum of 15 lymph nodes should be harvested for adequate staging.

10.1371/journal.pone.0049424.t004

###### Multivariate analyses of the overall survival in gastric cancer patients (Cox regression model, including the re-staged N system).

![](pone.0049424.t004){#pone-0049424-t004-4}

  Variable                              HR        95% CI      P value
  ----------------------------------- ------- -------------- ---------
  **OS in gastric cancer patients**                          
  Tumour location                      0.992   0.904--1.089    0.868
  Tumour size                          1.218   0.858--1.730    0.270
  Borrmann type                        1.115   0.954--1.303    0.171
  Histological grade                   1.153   1.004--1.324    0.044
  T staging                            1.491   1.276--1.741   \<0.001
  N staging                            0.696   0.525--0.924    0.012
  Lymph nodes harvested                0.853   0.721--1.008    0.063
  ** Restaged N staging**              1.960   1.495--2.571   \<0.001

Abbreviations: OS, overall survival; HR, hazard ratio; CI, confidence interval.

The other issue is how to stage gastric cancer patients with fewer than 15 lymph nodes harvested, especially patients with lymph node metastases. Empirical treatments from different oncologists make a substantial difference on the therapy and prognosis of those patients. The lymph node metastasis ratio is widely reported as an independent prognostic factor in gastric cancer [@pone.0049424-Lee1], [@pone.0049424-Wang2], [@pone.0049424-Xu1]--[@pone.0049424-Kong1]. However, different investigators use different cut-off values for the metastatic lymph node ratio to stage gastric cancer patients. For example, some investigators use 20% as a cut-off value while others use 50% as the cut-off value. Until now, there has been no uniform standard for the metastatic lymph node ratio cut-off values that would provide universal criteria for dividing the patients into different stage categories. The combination of the metastatic lymph node ratio and the AJCC's TNM staging system has not yet been considered. In our trial, we divided those patients who had fewer than 15 lymph nodes harvested by the cut-off values defined by the AJCC's 7^th^ TNM staging system as 0, 0.13 (2/15) and 0.40 (6/15). We then categorised those patients into the previous N staging group with the patients who had more than 15 lymph nodes harvested (0: N0; 0--0.13: N1; 0.13--0.40: N2; 0.40-: N3). Univariate and multivariate analyses were used to detect the effect of this staging method. We found our method has advantages over the previous N staging, and it should be considered as a method to reduce stage migration and to more accurately predict patient prognosis.

We found that the number of lymph nodes harvested was not an independent predictor. The reason may be that the predictive function of the lymph nodes harvested is covered by the re-categorised N staging in the multivariate analysis. If the re-categorised N staging is removed from the Cox's regression analysis, the number of lymph nodes harvested is an independent prognostic factor. This also demonstrates the advantage of the re-categorised N staging system compared to the original N staging system. The function of the original N staging is preserved in the re-categorised N staging.

As a retrospective study, there were confounding factors that influenced the statistical analyses and conclusions. Lymph node metastasis is one of the most important prognostic factors for patients with gastric cancer. The staging of the disease may be improved by identifying micrometastases in the lymph nodes and identifying extranodal metastasis of the disease. Although our study showed that the re-categorised N staging system is more accurate than the traditional N staging system, further prospective studies would provide additional evidence supporting the use of our re-categorised N staging system and metastatic lymph node ratio as a standard for the N staging of gastric cancer.

Conclusion {#s4a}
----------

Harvesting a large number of lymph nodes (more than 30) in radical gastrectomy would not cause N-stage migration. Additionally, for those patients who had fewer than 15 lymph nodes harvested, accurate staging would best be accomplished by dividing by the metastatic lymph node ratio that is mentioned in the TNM staging system.
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